Aldeyra Therapeutics (ALDX) vs Gossamer Bio (GOSS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aldeyra Therapeutics (ALDX) has outperformed Gossamer Bio (GOSS) over the past year, losing 83.1% versus a loss of 94.9%. Over five years, ALDX leads with a -88.6% price change compared with -99.1% for GOSS. Gossamer Bio is the larger company by market cap ($56.9 million vs $55.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | GOSS |
|---|---|---|
| Share price | $0.9163 | $9.31 |
| Market cap | $55.28M | $56.94M |
| 1-day change | -3.31% | -5.77% |
| YTD return | -81.70% | -96.02% |
| 1-year return | -83.14% | -94.90% |
| 5-year return | -88.64% | -99.12% |
| EPS (TTM) | $-0.38 | $-52.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $309.60 |
| 52-week low | $0.862 | $9.12 |
| Distance from 52-week high | -84.55% | -96.99% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +620.29% | +785.93% |
| Average volume | 1.18M | 378.37K |
| Shares outstanding | 60.33M | 6.12M |
| Employees | 6 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALDX has outperformed GOSS by 11.8 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
ALDX vs GOSS FAQ
Which is bigger, Aldeyra Therapeutics or Gossamer Bio?
Gossamer Bio (GOSS) is larger, with a market capitalization of $56.94M compared with $55.28M for Aldeyra Therapeutics (ALDX).
Which stock has performed better over the past year, ALDX or GOSS?
ALDX returned -83.14% over the past 12 months, compared with -94.90% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Gossamer Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.